26. Corona, G., et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol, 2015. 418 Pt 2: 120.
27. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. - 9-й выпуск (дополненный). - М.; 2019 DOI: 10.14341/DM221S1
28. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials // J Clin Endocrinol Metab 2006 Jun;91(6):2011-6.
29. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, body metabolism and serum lipid profile in middle-aged men: a meta-analysis // Clin Endocrinol (Oxf) 2005 Sep;63(3):280-93.
30. Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: 10.2147/cia.s4466.
31. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: 10.1210/jc.2009-2575.
32. Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(11):1451-1457. doi: 10.1093/gerona/60.11.1451.
33. Basaria S, Coviello AD, Travison TG, et al. Adverse event associated with testosterone administration // New Engl J Med 2010 Jul;363(2):109-22.
34. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep 2010 Nov;24(5):1115-20.
35. Shabsigh R, Crawford ED, Nehra A, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009 Jan-Feb;21(1):9-23.
36. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late onset hypogonadism: a randomized controlled trial. JAMA 2006 Nov 15;296(19):2351-61.
37. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: 10.1007/s10549-005-9074-y.
38. Ohlander SJ, Lindgren MC, Lipshultz LI. Testosterone and Male Infertility. Urol Clin North Am. 2016 May;43(2):195-202. doi: 10.1016/j.ucl.2016.01.006. Epub 2016 Mar 19. PMID: 27132576.
39. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: 10.1517/14740338.2014.950653.
40. Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi: 10.1111/j.1743-6109.2010.01765.x.
41. Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, Tafaro E, Resta F, Sabba C, Maggi M, Guastamacchia E. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500-11. doi: 10.2174/138161211796197160.
42. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi: 10.1530/eje-11-0221.
43. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: 10.1111/j.1365-2141.2005.05535.x.
44. Роживанов Р.В., Курбатов Д.Г. Гематологические и урологические аспекты безопасности заместительной андрогенной терапии препаратом тестостерона ундеканоата пролонгированного действия у пациентов с гипогонадизмом // Проблемы эндокринологии. - 2009. - № 6, том 55.- с. 31-35.
45. Kardoust Parizi, M., et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol, 2019. 37: 637.
46. Morgentaler A, Morales A. Should hypogonadal men with prostate cancer receive testosterone? J Urol 2010 Oct;184(4):1257-60.
47. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004 Sept;172(3):920-2.
48. Sarodsy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachitherapy. Cancer 2007 Feb;109(3):536-41.